Research programme: RNA interference-based metabolic disorders therapeutics - Marina Biotech

Drug Profile

Research programme: RNA interference-based metabolic disorders therapeutics - Marina Biotech

Alternative Names: MDR-04227; MDR-09885

Latest Information Update: 03 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MDRNA
  • Developer Marina Biotech
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 25 Feb 2015 Marina Biotech has patent protection for DiLA2 technology in USA, Europe, Japan, China and Australia
  • 22 Jul 2010 Discontinued - Preclinical for Hypercholesterolaemia in USA (Parenteral)
  • 22 Jul 2010 MDRNA has merged with Cequent Pharmaceuticals forming Marina Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top